NuCana plc has initiated an expansion study of its anti-cancer drug NUC-7738 combined with pembrolizumab for patients with melanoma resistant to PD-1 inhibitors, with initial data expected in Q4 2025 ...

Quantity, purity and quality of CTCs captured using the Parsortix system shown to be superior to an alternative antibody-based approach Study supports integration of the Parsortix system into ...

AstraZeneca ((AZN)), Icon Plc ((ICLR)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert ...